Drugs Made In America Acquisition Corp. financial statements
Income statement, balance sheet and cash flow statement for the last 1 fiscal years, taken from the XBRL data Drugs Made In America Acquisition Corp. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
General and administrative
2.82
Operating income
-2.82
Interest income
8.76
Other non-operating income
8.76
Net income
5.94
Balance sheet
FY2025
Cash and equivalents
0.01
Other current assets
0.01
Total current assets
0.01
Total assets
240
Accounts payable
0.22
Total current liabilities
0.38
Total liabilities
7.28
Retained earnings
-7.27
Shareholders' equity
-7.26
Total equity
-7.26
Total liabilities and equity
240
Shares outstanding
10.7
Cash flow statement
FY2025
Net income
5.94
Change in payables
0.14
Cash from operations
-0.54
Cash from investing
-231
Cash from financing
232
Net change in cash
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $10.84 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
4.1%
Net income / average total assets.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.02x
Current assets / current liabilities.
Quick ratio
0.01x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.01x
(Cash + short-term investments) / current liabilities.
Market cap + total debt - cash - short-term investments.
P/E
43.2x
Market cap / net income. Only when net income is positive.
Earnings yield
2.3%
Net income / market cap (the inverse of P/E).
Was Drugs Made In America Acquisition Corp. profitable in fiscal 2025?
Yes. Net income was $5.9M, a net margin of -.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.